Cytochrome P450 2B6 is aGrowth-Inhibitory and Prognostic Factor for ProstateCancer.

2020 ◽  
Author(s):  
Lungwani Muungo
Keyword(s):  
Prostate Cancer ◽  
Cytochrome P450 ◽  
Androgen Receptor ◽  
Prognostic Factor ◽  
Cancer Patients ◽  
Standard Treatment ◽  
Beneficial Effects ◽  
Cytochrome P450 2B6 ◽  
The World ◽  
Abundant Evidence

Prostate cancer is one of the most common malignanciesin the world. There is abundant evidence thatandrogens influence the development and progressionof prostate cancer [1–3]. Since most of prostate cancer isandrogen-dependent, standard treatment for metastaticprostate cancer patients is androgen deprivationtherapy (ADT). However the beneficial effects of ADTare transient and prostate cancer progresses to recurrentcancer. Recent reports showed that levels oftestosterone and its metabolites, dihydrotestosterone(DHT) and androstenediol, were still sufficiently highto activate the androgen receptor in recurrent prostate

Cytochrome P450 2B6 is a growth-inhibitory and prognostic factor for prostate cancer

The Prostate ◽  
2007 ◽  
Vol 67 (10) ◽  
pp. 1029-1037 ◽  
Author(s):  
Jinpei Kumagai ◽  
Tetsuya Fujimura ◽  
Satoru Takahashi ◽  
Tomohiko Urano ◽  
Tetsuo Ogushi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cytochrome P450 ◽  
Prognostic Factor ◽  
Cytochrome P450 2B6 ◽  
Growth Inhibitory

scholarly journals Expression of AR-V7 (Androgen Receptor Variant 7) Protein in Granular Cytoplasmic Structures Is an Independent Prognostic Factor in Prostate Cancer Patients

Cancers ◽  
2020 ◽  
Vol 12 (9) ◽  
pp. 2639
Author(s):  
Paul König ◽  
Markus Eckstein ◽  
Rudolf Jung ◽  
Amer Abdulrahman ◽  
Juan Guzman ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Regression Analysis ◽  
Androgen Receptor ◽  
Prognostic Factor ◽  
Cancer Biology ◽  
Splice Variants ◽  
Independent Prognostic Factor ◽  
Cytoplasmic Granules ◽  
Cox's Regression ◽  
Cytoplasmic Structures

Prostate cancer (PCa) is the second most common cancer, causing morbidity and mortality among men world-wide. The expression of the androgen receptor (AR) and its splice variants is a crucial factor of prostate cancer biology that has not been comprehensively studied in PCa tumors. The aim of this study was to characterize the protein expression of the AR and its splice variant, AR-V7, and their subcellular distributions in PCa by immunohistochemistry and to correlate the results to the clinicopathological data and prognosis. Immunohistochemical staining for AR and AR-V7 was performed on a tissue microarray (TMA) with specimens from 410 PCa patients using an immunoreactive score (IRS) or only the percentage of AR-V7 staining in cytoplasmic granules. Nuclear or cytoplasmic AR staining was not associated with prognosis. AR-V7 staining was only occasionally observed in the nucleus. However, AR-V7 staining in the cytoplasm or in cytoplasmic granules was associated with relapse-free survival (RFS). AR-V7 staining of the cytoplasm was associated with a shorter RFS, whereas AR-V7 staining of cytoplasmic granules was associated with a longer RFS. In a multivariate Cox’s regression analysis, only negative (<5%) AR-V7 staining of cytoplasmic granules remained an independent prognostic factor for RFS (HR = 5.3; p = 0.006). In a further subgroup analysis by multivariate Cox’s regression analysis, AR-V7 was an independent prognostic factor in the following groups: age ≤ 65 (HR = 9.7; p = 0.029), negative CK20 staining (HR = 7.0; p = 0.008), and positive perineural invasion (HR = 3.7; p = 0.034). Altogether, AR-V7 protein in granular cytoplasmic structures is an independent prognostic factor for RFS in PCa patients.

Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy

2006 ◽  
Vol 13 (9) ◽  
pp. 1197-1201 ◽  
Author(s):  
TAKATSUGU OKEGAWA ◽  
MANAMI KINJO ◽  
KIKUO NUTAHARA ◽  
EIJI HIGASHIHARA
Keyword(s):  
Prostate Cancer ◽  
Prognostic Factor ◽  
Serum Level ◽  
Cancer Patients ◽  
Endocrine Therapy ◽  
Metastatic Prostate Cancer ◽  
Pretreatment Serum

1014 PSA density as a prognostic factor in prostate cancer patients treated with radiotherapy

1995 ◽  
Vol 32 ◽  
pp. 229
Author(s):  
Scott Lankford ◽  
Alan Pollack ◽  
Gunar K. Zagars
Keyword(s):  
Prostate Cancer ◽  
Prognostic Factor ◽  
Cancer Patients ◽  
Psa Density

scholarly journals Age-adjusted Charlson Comorbidity Index as a prognostic factor for radical prostatectomy outcomes of very high-risk prostate cancer patients

PLoS ONE ◽  
2018 ◽  
Vol 13 (6) ◽  
pp. e0199365 ◽  
Author(s):  
Jae Won Park ◽  
Dong Hoon Koh ◽  
Won Sik Jang ◽  
Joo Yong Lee ◽  
Kang Su Cho ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Prognostic Factor ◽  
Radical Prostatectomy ◽  
Cancer Patients ◽  
Charlson Comorbidity Index ◽  
High Risk Prostate Cancer ◽  
Risk Prostate Cancer ◽  
Comorbidity Index ◽  
Very High

YB-1 variant and androgen receptor axis-targeted agents in metastatic castration-resistant prostate cancer patients

2020 ◽  
Vol 21 (13) ◽  
pp. 919-928
Author(s):  
Ana Afonso ◽  
Jani Silva ◽  
Ana Rita Lopes ◽  
Sara Coelho ◽  
Ana Sofia Patrão ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Cancer Patients ◽  
Cox Regression ◽  
Progression Free Survival ◽  
Castration Resistant Prostate Cancer ◽  
Allelic Discrimination ◽  
Cox Regression Analysis ◽  
Castration Resistant ◽  
Increased Risk

Aim: To evaluate the influence of YB-1 rs10493112 variant as a genetic marker for response to second-generation androgen receptor axis-target agents. Methods: A hospital-based cohort study of 78 patients with metastatic castration-resistant prostate cancer was conducted. Genotyping was performed by TaqMan® allelic discrimination technology. Main results: In abiraterone-treated and high-risk patients, YB-1 rs10493112 AA genotype carriers showed lower progression-free survival than C allele genotype patients (4 vs 17 months; p = 0.009). For carriers of AA genotype, multivariate Cox regression analysis revealed a fivefold increased risk of progression (p = 0.035). Conclusion: The study findings suggest that, for metastatic and castration-resistant prostate cancer patients, this polymorphism might be a putative marker for the clinical outcome.

scholarly journals MP29-05 ANDROGEN RECEPTOR GENE ABERRATIONS IN CIRCULATING CELL FREE DNA FROM JAPANESE CASTRATION RESISTANT PROSTATE CANCER PATIENTS

2018 ◽  
Vol 199 (4S) ◽  
Author(s):  
Takayuki Sumiyoshi ◽  
Shusuke Akamatsu ◽  
Toshinari Yamasaki ◽  
Kei Mizuno ◽  
Takayuki Goto ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Cancer Patients ◽  
Receptor Gene ◽  
Androgen Receptor Gene ◽  
Castration Resistant Prostate Cancer ◽  
Cell Free Dna ◽  
Castration Resistant ◽  
Free Dna ◽  
Circulating Cell Free Dna
Sign in / Sign up

Export Citation Format

Share Document